SethM.PollackMD

Sarcoma

Director of the Sarcoma Program, Lurie Cancer Center Steven T. Rosen Professor of Cancer Biology Associate Professor, Department of Medicine Feinberg School of Medicine, Northwestern University

Join to view full profile

Dr. Pollack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pollack's full profile

Already have an account?

Office
675 N St Clair St
Suite 21-100
Chicago, IL 60611
Phone+1 312-695-0990

Fax+1 312-695-1144

Summary

I am a medical oncologist and specialize in treating adult patients with sarcoma. My research is focused on the development of novel immunotherapies for patients with advanced sarcoma, particularly Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL). My patient care philosophy is to provide care centered on my patients goals and desires and to fight as hard as I can to help cure my patients.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2008 - 2010
George Washington UniversityResidency, Internal Medicine, 2005 - 2008
George Washington University School of Medicine and Health SciencesClass of 2005
Haverford CollegeBachelor of Arts, Mathematics, 1995 - 1999

Certifications & Licensure

IL State Medical License 2020 - 2026
WA State Medical License 2008 - 2022
VA State Medical License 2005 - 2008
DC State Medical License 2005 - 2007
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Sig Kohl Legacy Award Northwest Sarcoma Foundation, 2017

Clinical Trials

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery Start of enrollment: 2012 Jan 01
Completed
Phase 1
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Start of enrollment: 2013 Sep 25
Terminated
Early Phase 1
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Start of enrollment: 2014 Jul 01
Withdrawn
Phase 1
TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2014 Nov 17
Completed
Phase 1
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Start of enrollment: 2016 Dec 15
Completed
Phase 1
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2017 Sep 28
Terminated
Phase 1, Phase 2
Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma Start of enrollment: 2018 Mar 28
Completed
Phase 1, Phase 2
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Start of enrollment: 2018 Jun 19
Withdrawn
Phase 2
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Start of enrollment: 2019 Sep 30
Terminated
Phase 1
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 2020 Jan 14
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) Start of enrollment: 2023 Nov 29
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

100 citations
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
Seth M. Pollack, Achim A. Jungbluth, Benjamin Hoch, Erik A. Farrar, Marie Bleakley
Cancer. 2012-09-15
44 citations
NYESO-1/LAGE-1s and prame are targets for antigen specific t cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine
Seth M. Pollack, Yonqing Li, Megan J. Blaisdell, Erik A. Farrar, Jeffrey Chou
Plos One. 2012-02-27
25 citations
Unmet medical needs and future perspectives for leiomyosarcoma patients—A position paper from the national leiomyosarcoma foundation (NLMSF) and sarcoma patients euron...
Bernd Kasper, Annie Achee, Kathrin Schuster, Roger Wilson, Gerard van Oortmerssen
Cancers. 2021-02-02

Lectures

A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic/unresectable sarcoma.
2019 ASCO Annual Meeting - 6/1/2019
Is There a Role for Immunotherapy in Sarcomas?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Exploring the Use of Weakened Viruses for Cancer TreatmentJune 12th, 2024
SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018
Can You Vaccinate Yourself Against Cancer?February 21st, 2018
Join now to see all